Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.

T Takagi, T Saotome, C Sakai, K Kumagai, J Tamaru

Journal: Annals of oncology : official journal of the European Society for Medical Oncology 2000;11(1):115-6

PMID: 10690400

Free Full Text on Elsevier Science View on PubMed

Abstract

Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3. Nine (36%) of twenty-five patients achieved CR. Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in follicular lymphoma grade 1), and substantial responses in T-cell lymphomas (1 of 4 in peripheral T-cell lymphoma and 2 of 7 in adult T-cell leukemia/lymphoma). Leukopenia was frequent but tolerable, and diarrhea minimal. Combination chemotherapy with a reduced dose CPT-11 and ADM was useful in the treatment of relapsed non-Hodgkin's lymphoma.

Address: Hematology-Oncology Division, Chiba Cancer Center Hospital, Japan.

DOI: 10.1023/a:1008368905546

Link outs

Free resources

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0923...

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Adult, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Doxorubicin, Drug Administration Schedule, Humans, Irinotecan, Leukopenia, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Recurrence